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Abstract  
Primary Sclerosing cholangitis (PSC) is a rare chronic auto-immune disease with no effective 
therapy and a large unmet need for new treatments. Patients require significant healthcare 
resources over their lifetime with high rates of hospital admission, malignancy, liver 
transplantation and death. As a rare disease, expertise in management can be limited to large 
referral liver transplant programmes, and even then there is frequently variation in practice. In 
this case-based review, we aim to discuss common clinical dilemmas encountered by clinicians 
managing patients with PSC and address related competencies in the 2010 Gastroenterology 
Curriculum. 
  
Introduction 
Primary sclerosing cholangitis (PSC) is a rare auto-immune liver disorder with no effective 
therapeutic intervention yet an ongoing high morbidity, mortality and hepato-biliary/colonic 
cancer risk. Current management aims towards symptomatic treatment, facilitation of clinical 
trials and appropriate but timely referral for liver transplantation. Diagnosis and risk stratification 
for progressive disease is challenging, with an often unpredictable course complicated in most 
cases by co-morbid inflammatory bowel disease. This clinical review will address the related 
competencies described in the 2010 Gastroenterology Curriculum (Box 1) and focus on clinically 
relevant dilemmas commonly faces when managing these patients. 
Background & Clinical presentation 
PSC is a chronic auto-immune liver disease characterized by progressive cholestasis, 
inflammation and fibrosis affecting both intra and extrahepatic bile ducts1. This leads to multiple 
biliary strictures which predisposes to infection, malignancy and progresses to cirrhosis and 
chronic liver failure. The pathogenesis of PSC is complex and multifactorial and a reflection of 
converging genetic and environmental risk which result in chronic fibrosing biliary injury from a 
combination of immune dysregulation, altered gut microbiota and abnormal bile homeostasis2. 
Commonly a combination of otherwise unexplained biochemical cholestasis for at least 6 months 
plus characteristic changes on Magnetic Resonance Cholangiopancreatography (MRCP) or liver 
biopsy is accepted as leading to a confident diagnosis of PSC1. Endoscopic retrograde 
cholangiopancreatography (ERCP) should be reserved for therapeutic procedures and is not 
recommended for diagnosis, in keeping with substantial risks of cholangitis and pancreatitis. 
More detailed description of the clinical presentation can be found in Box 2.  
Most patients with PSC have evidence of both intra and extrahepatic bile duct disease. Isolated 
large bile duct stricturing occurs in <5% of PSC patients, and should raise the possibility of an 
alternative or additional diagnosis such as cholangiocarcinoma1. Fewer than 25% of patients 
experience isolated intra-hepatic disease, so called “small-duct PSC”1, which may be diagnosed in 
the context of chronic cholestasis but normal MRCP, with a liver biopsy suggestive of PSC +/- co-
morbid inflammatory bowel disease (IBD). Diagnostic criteria for small duct PSC should focus on 
the presence of characteristic disease defining histology; disease that remains restricted to small 
ducts only has a better prognosis1. 
In keeping with limited disease insights, overlapping and cross-over presentations are 
encountered, particularly in younger patients3. Further discussion of this is beyond the scope of 
this article.  Similarly in all patients, IgG4 associated systemic disease should be considered and 
excluded, usually on the basis of IgG4 measurement and imaging review. 
Management dilemmas 
Current management relies on symptomatic control of itch, pain and cholangitis with close 
monitoring for complications. A majority of patients will become established on a path to 
relentless fibrosis and cirrhosis making timely referral for consideration of transplantation 
important, particularly given the unpredictable nature of obstructing biliary disease. Orthotopic 
liver transplantation usually for advanced parenchymal disease or recurrent cholangitis will result 
in an average of 80% 10 year survival1. PSC accounts for around 10% of liver transplants 
worldwide and is the 5th most common indication for transplantation in the UK4; although the 
rarest of the autoimmune liver diseases PSC is now the leading disease indication for 
transplantation within the family of autoimmune liver diseases. Despite this, recurrent PSC in the 
graft has been described in up to 30% within the first 5 years post transplantation1. 
Immunosuppressive agents have no role in PSC management unless there is strong evidence of 
overlap with AIH, which must include convincing liver histology.  
Frequent management dilemmas faced by clinicians include: 
1) Ursodeoxycholic Acid 
Ursodeoxycholic acid (UDCA) is one of two drugs licenced for PBC, however it remains 
controversial in PSC. Large trials have failed to prove statistically significant improvement in 
fibrosis on liver biopsy or in symptoms, although biochemistry can be markedly improved with 
UDCA1.  At higher doses of 28-30mg/kg/day, a large multi-centre study was terminated early, due 
to increased risks of liver transplantation and varices development in the UDCA-treated cohort 
(many of whom who already had late-stage cirrhosis)1. Due to these concerns, current guidance 
cannot make an evidence-based recommendation to use UDCA1, and it is notable that 
transplantation rates for PSC have, unlike PBC, not changed over time despite liberal use of UDCA 
at times. Additionally no data supports a role for UDCA in cancer chemoprevention. 
2) Managing cholangitis and the role of ERCP 
Recurrent cholangitis is a common complication of PSC and can result in the need for repeated 
hospital admissions. Fever and raised inflammatory markers are not always seen however a 
sudden increase in the level of pruritus or worsening biochemistry that responds to antibiotics is 
key. Cholangitis can often be managed in the community, with intermittent short courses of 
appropriate oral antibiotics (e.g. ciprofloxacin) kept at home for patients to commence 
themselves however short courses of intravenous antibiotics may be required. Patients 
experiencing multiple episodes of cholangitis per year can respond well symptomatically to long 
term rotating low-dose prophylactic antibiotics, however long term benefit from this has not 
been proven. Patients with severe recurrent cholangitis can be considered for liver 
transplantation, independently of the severity of their liver dysfunction, as should all patients 
with advanced PSC1. 
Recurrent cholangitis is a feature of the natural history of PSC and biliary intervention needs 
much thought, as benefit and risk are finely balanced in PSC. ERCP may have a role in the 
therapeutic management of a dominant biliary stricture when clinically indicated: the dilemma is 
in definitions and whilst cholangiography can be used (strictures are considered dominant if 
there is a <1.5mm stenosis in the common bile duct (CBD) or <1mm in the right/left hepatic 
ducts1), in practice a better definition is the combination of clinical, laboratory and imaging 
findings, after appropriate MDT review. Development of a new biliary stricture requires exclusion 
of cholangiocarcinoma and potentially decompression of biliary obstruction. This may reduce 
ongoing liver damage as well as alleviate some symptoms of pruritus and recurrent cholangitis. 
However, not all strictures are responsible for symptoms and not all are amenable to endoscopic 
intervention. Endoscopic programmes include short-term stenting with plastic stents or repeated 
balloon dilatation attempts (the latter more commonly chosen), however the evidence for these 
is unclear1.  
3) Managing concomitant IBD and colonic neoplasia risk 
PSC-IBD is a clinical entity subtly distinct from classical ulcerative colitis or Crohns disease5 and is 
co-morbid in up to 75% of PSC6. Bowel symptoms can be mild or even completely absent; 
therefore recommendations are for a baseline colonoscopy (with segmental biopsies) in those 
not already known to have IBD, regardless of bowel symptomology1. A diagnosis of PSC-IBD has 
significant prognostic implications, with a 20-30% risk of colonic carcinoma over 20 years 
compared to a 5% risk of the same in ulcerative colitis without PSC7. Thus, in the presence of PSC-
IBD, colonoscopy is generally repeated annually from the time of PSC diagnosis1.  Dye-spray 
surveillance is likely appropriate, as may endomicroscopic techniques be in the future.   
Colitis management in PSC-IBD resembles that of IBD alone. Overall good control of IBD activity 
(i.e. mucosal healing where possible) is important, although it is not clear if this impacts beyond 
the colon into liver outcomes.  Annual colonoscopic surveillance continues post-transplant, and 
attention is important to potentially clinically significant flares post-transplant, that may require 
prompt biologic therapy (e.g. Vedolizumab) or colectomy, frequently in the presence of pristine 
liver graft function.  Recurrent disease appears associated with the presence of an intact colon 
post-transplant.  In those patients contemplating pouch surgery, it is important to counsel for a 
higher rate of pouchitis in PSC-IBD subjects, and an association with recurrence for those with 
pouchitis post-transplant. 
4) Hepatobiliary Malignancy risk in PSC 
PSC patients are at significant risk of hepatobiliary malignancies most commonly 
cholangiocarcinoma (CCA), gallbladder adenocarcinoma and occasionally hepatocellular 
carcinoma (HCC). Patients with PSC have a CCA lifetime risk of 10-15%, a third of which are 
diagnosed within 12 months of the PSC diagnosis (albeit this is a risk clearly augmented with 
increasing age at diagnosis)1. Distinguishing CCA from PSC alone can be difficult, so a high index 
of suspicion must be held over any dominant stricture or other sudden worsening in biochemistry 
or imaging. It is currently not possible to predict which individuals are most at risk and this does 
not correlate well with severity of symptoms or parenchymal disease1. ERCP with brush cytology 
is traditionally used to investigate a possible cholangiocarcinoma or dominant large bile duct 
stricture, however this has a relatively low diagnostic yield and negative brushings do not provide 
absolute reassurance of the absence of cancer. Newer techniques have evolved to increase yield 
at ERCP which may improve diagnosis, for example Fluorescence In Situ Hybridization (FISH), 
Digital Image Analysis (DIA) or direct visualisation of the biliary tree via digital cholangioscopy 
(SpyGlass). CA19-9 can be raised in both PSC and CCA so is not frequently useful for diagnosis and 
overall routine surveillance for cholangiocarcinoma is cannot currently be recommended based 
on evidence of efficacy. A combination of non-invasive imaging, CA19-9 and ERCP with sampling 
may provide better detection rates and investigation via these modalities should be considered 
whenever there is clinical concern about the development of cholangiocarcinoma1.  
Gallbladder cancer is diagnosed in 2% of PSC patients with half of gallbladder lesions proving to 
be adenocarcinoma1. Therefore, yearly ultrasound imaging is recommended for patients with 
PSC, and HPB consultation important with a view to cholecystectomy, if gallbladder polyps are 
identified1.  6 monthly ultrasound scanning should be commenced for HCC surveillance once 
cirrhosis is confirmed. 
 
New Treatments, clinical trials and prognosis 
PSC is an orphan disease with no current disease-modifying therapy nor any validated risk 
stratification tools8. Currently, the median time from diagnosis to liver transplantation or death is 
between 13-21 years9 with significant healthcare resource use and symptomatic needs. PSC thus 
represents a high unmet need for patients, and those at particular risk of progression (usually 
identified by active biochemical cholestasis) are encouraged to enter clinical trials. Box 3 
describes the currently recruiting interventional clinical trials as listed on clinicaltrials.gov, 
demonstrating an ongoing interest in disease modification tackling a broad spectrum of biologic 
targets. 
Case Examples:- 
Case 1) Mr A presented generally unwell aged 17 and was found to have an ALT >300U/L with 
normal ALP, bilirubin and liver synthetic function. ANA was weakly positive and IgG was 19.1g/L. 
Ultrasound was normal. Non-invasive liver screen was negative and there was no significant 
family or travel history. He underwent a percutaneous liver biopsy which showed significant 
fibrosis, with moderate portal inflammation and piecemeal necrosis. A diagnosis of auto-immune 
hepatitis was made and prednisolone 30mg was commenced. After four weeks there was no 
improvement so he was referred to tertiary hepatology services. 
On further review, Mr A was found to also have a raised GGT at 641U/L. MRCP confirmed 
prominence of the intra-hepatic biliary tree with evidence of short strictures, consistent with PSC. 
He had also been suffering from some mild diarrhoea but this had resolved since starting the 
prednisolone. He underwent colonoscopy confirming active ulcerative pan-colitis and 
commenced mesalazine followed by azathioprine, gaining good colitis control off corticosteroids. 
Liver tests improved markedly after this with ALT 104U/L and GGT 258U/L. 
This case demonstrates an inflammatory sub-group of PSC, especially as a presentation in 
adolescents initially treated as AIH. It can be difficult to distinguish between AIH and 
inflammatory PSC however a high index of suspicion is relevant, especially in young men with a 
history of bowel symptoms. In young patients GGT has better sensitivity for biliary disease than 
ALP; additionally in the newly presenting patient with early PSC-IBD, it is not infrequent to 
observe an improvement in liver biochemistry with effective IBD management. 
Case 2) Mrs B was a healthy 49 year old woman who underwent a routine laparoscopic 
cholecystectomy for cholelithiasis. At the time of surgery it was noted that her liver looked 
abnormal and a biopsy was taken. Liver histology showed non-specific abnormalities including 
reactive changes and mild fibrous expansion of the portal tracts. She became lost to follow up 
but presented 7 years later with profound painless jaundice and weight loss.  Non-invasive liver 
screen was negative. An ultrasound showed evidence of cirrhosis with splenomegaly. ERCP 
showed a narrow irregular CBD and a diagnosis of PSC was made. UDCA was commenced 
followed by referral to tertiary hepatology services.  
Upon review she remained jaundiced with a bilirubin of 160µmol/L and UKELD of 54 (MELD 31). 
She described worsening itch, fatigue and steatorrhea. UDCA was stopped and hydralazine as 
well as cholestyramine commenced, with resulting improvement in itch and bowel symptoms. 
While awaiting an MRCP, she deteriorated with a bilirubin of 400µmol/L and UKELD 60 (MELD 
35), so she was admitted for liver transplant assessment. MRCP confirmed dilated intrahepatic 
bile ducts with beading abnormalities and suggested a hilar stricture. Despite clinical concern 
over the possibility of CCA, no objective evidence of this could be found on imaging. Given her 
rapid clinical deterioration she was accepted onto the liver transplant list and she received a 
whole liver graft 5 days later.   
Explant histology confirmed a T4 N1 poorly differentiated cholangiocarcinoma with lymph node 
spread and possible involvement of the distal bile duct margin. Mrs A received best supportive 
care and died soon after this. 
This case highlights the need to maintain follow up on patients with possible early liver disease 
to ensure accurate diagnosis and timely referral for further management or transplantation. 
Diagnosis of CCA can be elusive and it remains that transplantation may be considered and 
offered, despite accepted uncertainty, with cancer identified only on explant evaluation. 
Case 3) Mr C presented aged 16 with diarrhoea and abdominal pain. Flexible sigmoidoscopy was 
normal however colonoscopy confirmed moderately active right-sided colitis and mesalazine was 
commenced. Multiple courses of corticosteroids were required to gain colitis control, followed by 
the introduction of azathioprine. It was noted that Mr C had deranged LFTs, with ALP 474U/L and 
ALT 195U/L. MRCP showed beading within the intrahepatic bile ducts and a diagnosis of PSC-IBD 
was made followed by a referral to tertiary hepatology services. 
This was followed by multiple admissions to hospital feeling generally unwell, feverish and with a 
transiently raised bilirubin. Inflammatory markers were normal however symptoms swiftly 
resolved after the introduction of antibiotics for presumed recurrent cholangitis and pausing of 
the azathioprine. In between these episodes Mr C remained well and was planned for active 
surveillance, with yearly ultrasound and colonoscopy. However, the episodes of cholangitis 
persisted so he commenced a rotating pattern of sequential prophylactic antibiotics and 
azathioprine was stopped. Plans were made for a 10 day course of IV antibiotics in the 
community if oral antibiotics did not settle things down and for further bowel investigations to 
ensure that his IBD was completely under control. 
This case demonstrates that cholangitis can be difficult to manage and may result in repeated 
admissions to local and specialist services. Often symptoms are subtle and patients do not 
necessarily present with typical signs of infection yet can deteriorate very quickly without 
appropriate treatment. A low threshold should exist for trialling a course of ciprofloxacin in 
these patients as well as looking for driving factors such as active IBD or a dominant stricture.  
A selection of best of 5 questions can be seen in Box 4 with answers in Box 5. 
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Box 1. Gastroenterology 2010 curriculum competencies 
2) Core Competencies 
 
e) Hepatology 
Specific diseases 
Auto-immune liver disease including auto-immune hepatitis, PBC, PSC and 
overlap syndromes:- 
 
- Awareness of management and complications of autoimmune liver 
disease including the malignant complications in PSC. 
- Appreciate and understand that this range of liver disease is frequently 
under diagnosed and may have been inappropriately managed. 
3)Advanced Specialist areas 
a) Hepatology 
Complications of Cholestatic Liver Disease:- 
- To be able to carry out specialist assessment, investigate, diagnose, 
initiate treatment of patients with cholestatic liver disease (e.g. PBC, PSC) 
and exclude large duct obstruction. 
- Able to assess individual patients concerning the timing of potential 
transplantation. 
- Selects and uses investigations appropriately (specifically in PSC,) to be 
aware of possible inflammatory bowel disease and regimes for 
colonoscopic surveillance. 
 
*Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) 
  
Box 2. Epidemiology and clinical features of Primary Sclerosing Cholangitis (PSC) 
Epidemiology Prevalence of up to 16.2 per 100,000 inhabitants10. 
60% of sufferers are male1. 
Mean age 30-40 years11. 
Associations Non-smokers1. 
Inflammatory bowel disease is seen in up to 80%1. 
Symptoms Pruritus, right upper quadrant pain, fatigue, fevers/chills, recurrent cholangitis. 
Severity of symptoms does not correlate well with the severity of liver 
dysfunction, biochemistry or imaging or the malignant risk1. 
Diagnosis 
- Biochemistry 
 
 
- Serology 
 
 
- Imaging 
 
- Liver biopsy 
50% of patients are diagnosed at the early, asymptomatic stage1.  
Cholestasis (i.e. raised ALP, GGT and/or bilirubin). 
Liver synthetic dysfunction if advanced parenchymal disease.  
ALT/AST often mildly raised in the range of 2-3 times normal1.  
Non-specific and not required for a diagnosis.  
Immunoglobulin G can be up to 1.5 times normal in 60% of patients1 but it is 
vital to check IgG subclasses to exclude IgG4 disease.  
MRCP - usually the first line diagnostic test, aims to identify bile duct stricturing. 
Useful if diagnostic uncertainty or normal MRCP. 
Classical changes of periductal concentric fibrosis (“onion-skinning). 
Differential 
Diagnosis 
Secondary sclerosing cholangitis. 
IgG4 cholangiopathy. 
Ischaemic cholangitis. 
Inherited cholestatic diseases (e.g. ABCB4 deficiency). 
*Alkaline Phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Alanine transaminase (ALT), 
Aspartate transaminase (AST) 
Box 3. Current interventional clinical trials in PSC 
Full name Sponsor Location Status 
A Single-arm, Phase IIa, Safety and Efficacy 
Trial of Selected MSCs in the Treatment of 
Patients With PSC & AIH (Merlin) 
University of 
Birmingham 
UK Not yet open 
A Phase 2, Randomized, Double Blind, 
Placebo Controlled, Parallel Group, Multiple 
Center Study to Evaluate the Safety, 
Tolerability, and Efficacy of NGM282 
Administered for 12 Weeks in Patients With 
Primary Sclerosing Cholangitis 
NGM 
Biopharmaceuticals, 
Inc 
USA & 
Europe 
Open to 
recruitment 
Fecal Microbiota Transplantation for the 
Treatment of Primary Sclerosing Cholangitis. 
Brigham and Women's 
Hospital 
USA Open to 
recruitment 
Safety, Tolerability, and Efficacy of GS-9674 
in Adults With Primary Sclerosing Cholangitis 
Without Cirrhosis (PSC-Phase 2) 
Gilead Sciences USA & 
Europe 
Open to 
recruitment 
The Human Gastrointestinal Tract Microbiota 
in the Setting of Treating Primary Sclerosing 
Cholangitis and Biliary Atresia With 
Vancomycin 
Sacramento Pediatric 
Gastroenterology 
USA Open to 
recruitment 
A Single Arm, Two-stage, Multi-centre, Phase 
II Clinical Trial Investigating the Safety and 
Activity of the Use of BTT1023 Targeting 
Vascular Adhesion Protein (VAP-1), in the 
Treatment of Patients With Primary 
Sclerosing Cholangitis (PSC). 
University of 
Birmingham 
UK Open to 
recruitment 
A Phase 2, Randomized, Double-Blind, 
Placebo-Controlled, Dose-Finding, Clinical 
Trial Evaluating the Efficacy and Safety of 
Obeticholic Acid in Subjects With Primary 
Sclerosing Cholangitis 
Intercept 
Pharmaceuticals 
USA & 
Europe 
Ongoing, 
Closed to 
recruitment 
Treatment of Primary Sclerosing Cholangitis 
in Inflammatory Bowel Disease Patients With 
Oral Vancomycin by the Study of Its 
Antimicrobial and Immunomodulating 
Effects 
Stanford University, 
USA 
USA Ongoing, 
Closed to 
recruitment 
A Phase 2b, Dose-Ranging, Randomized, 
Double-Blind, Placebo-Controlled Trial 
Evaluating the Safety and Efficacy of GS-
6624, a Monoclonal Antibody Against Lysyl 
Oxidase Like 2 (LOXL2) in Subjects With 
Primary Sclerosing Cholangitis (PSC) 
Gillead Sciences USA & 
Europe 
Closed, 
Awaiting 
results 
  
Box 4. Best of 5 Questions for the gastroenterology SCE 
1) Ms D is a 35 year old lady who has undergone a liver biopsy. 
Which histological features would be most in keeping with a diagnosis of PSC? 
a) Focal duct obliteration with granuloma formation 
b) Hepatocyte ballooning, Mallory-Denk bodies and lobular inflammation  
c) Interface hepatitis with resetting and central portal bridging necrosis 
d) Periductal concentric fibrosis  
e) Piecemeal necrosis with periportal inflammation  
2) Mr E is a 45 year old man with a 25 year history of PSC. He has a history of recurrent 
cholangitis not controlled with daily rotating antibiotics and worsening pruritus despite 
daily cetirizine and cholestyramine sachets thrice daily. His investigations are as follows:- 
Hb 101g/L                   WCC 3.1x10*9/L Platelets 100x10*9/L     INR 1.4  
Sodium 131mmol/L Urea 3.1mmol/L Creatinine 43µmol/L       Alb 32g/L                     
ALT 23U/L  AST 20U/L             Bilirubin 67µmol/L      ALP 587U/L  
Ultrasound – course liver parenchyma with irregular edge, splenomegaly, no ascites 
MRCP – multi-focal biliary stricturing with peripheral dilatation 
Which of the below options is the likely optimal management plan for him? 
a) Admit to hospital for a 7 day course of IV Merepenem  
b) Commence rifampicin  
c) Commence UDCA 
d) ERCP with balloon dilatation and/or plastic stent insertion 
e) Refer for liver transplant assessment 
3) Mr F is an 18 year old man who presents with a 2 month history of abdominal pain and 
diarrhoea up to 3 times per day with occasional streaks of blood. Investigations are as 
follows:- 
Hb 135g/L             WCC 5.1x10*9/L Platelets 361x10*9/L  INR 0.9 
Sodium 139mmol/L Urea 4.1mmol/L Creatinine 63µmol/L               Alb 37g/L 
ALT 55U/L  AST 60 U/L  Bilirubin 23µmol/L  ALP 295U/L  
Colonoscopy – moderately severe pancollitis. 5ASA commenced. 
MRCP – slight beading of the intrahepatic bile ducts 
What would be the next best management strategy for this patient? 
a) Commence Azathioprine  
b) Commence UDCA 
c) ERCP  
d) Liver biopsy 
e) Repeat biochemistry in 4-6 weeks 
 
  
Box 5. Best of 5 Questions for the gastroenterology SCE – Answers 
1) Focal duct obliteration with granuloma formation is associated with PBC. Hepatocyte 
ballooning, Mallory-Denk bodies and lobular inflammation are features of NASH. Interface 
hepatitis with resetting and central portal bridging necrosis are associated with AIH. 
Piecemeal necrosis with periportal inflammation is associated with PSC-AIH overlap. 
Periductal concentric fibrosis is highly suggestive of PSC therefore d) is the correct answer. 
2) Admission for a course of IV antibiotics can help provide relief but this is short term and he 
has significant liver synthetic dysfunction so more definitive management is required. While 
rifampicin is next to try for intractable pruritus according to guidelines, caution is required 
with this level of synthetic liver dysfunction and would again only be a holding measure. 
UDCA is not currently recommended in PSC and can worsen pruritus. There is no dominant 
stricture or signs of biliary obstruction so ERCP would not be recommended in this situation 
and would have risk risks of precipitating worsening cholangitis. Mr E has a Child-Pugh score 
of 8 giving Class B disease, plus has an indication for transplant (intractable cholangitis) and 
a UKELD score of 58 (MELD 20). Therefore e) is correct in this instance. 
3) In a young man with IBD and deranged LFTs which are of a cholestatic nature, PSC is top of 
the differential diagnosis list. While transaminases and IgG are slightly raised, this is non-
specific and insufficient evidence of possible PSC-AIH overlap to justify liver biopsy at this 
point or commencement of further immunosuppression. UDCA is not currently 
recommended in PSC and there is no indication for ERCP. Liver biochemistry may improve 
significantly with IBD control. a) Is the correct answer. 
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